Bibliography
- MCMAHON G, SUN L, LIANG C, TANG C: Protein kinase: structural determinants for target specificity. Curr. Opin. Drug Discov. Dev. (1998) 1:131–146.
- ADAMS JL, LEE D: Recent progress towards the identifi- of selective inhibitors of serine/threonine protein kinases. Curr. Opin. Drug Discov. Dev. (1999) 2:96–109.
- •Good general review on serine/threonine kinase inhibitors.
- SALITURO FG, GERMANN RA, WILSON KP, BEMIS GW, T, SU MS-S: Inhibitors of p38 map kinase: therapeutic intervention in cytokine-mediated diseases. Curr. Med. Chem. (1999) 6:807–823.
- ••In-depth review on p38 inhibitors.
- GALLAGHER TF, SEIBEL GL, KASSIS S et al.: Regulation of stress-induced cytokine production by pyridinylimi-dazoles; inhibition of CSBP kinase. Bioorg. Med. Chem. (1997) 5:49–64.
- JACKSON JR, BOLOGNESE B, HILLEGASS L et al: Pharma-cological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J. Pharmacol Exp. Ther. (1998) 284:687–692.
- ADAMS JL, BOEHM JC, KASSIS S et al: Pyrimidinylimida-zole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. Bioorg. Med. Chem. Lett. (1998) 8:3111–3116.
- UNDERWOOD DC, OSBORN RR, KOTZER CJ et al: SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosino-phil infiltration and persistence. J. Pharm. Exper. Ther. (2000) 293:281–288.
- DE LASZLO SE, VISCO D, AGARWAL L et al: Pyrroles and other heterocycles as inhibitors of p38 kinase. Bioorg. Med. Chem. Lett. (1998) 8:2689–2694.
- WODSWORTH SA, CAVENDER DE, BEERS S et al: RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J. Pharm. Exp. Ther. (1999) 291:680–687.
- HENRY JR, RUPERT KC, DODD JH et al.: 6-Amino-2-(4-fluoropheny0-4-methoxy-3- (4-pyridy1)-1H-pyrrolo[2, 3-b]pyridine (RWJ 68354): a potent and selective p38 kinase inhibitor. J. Med. Chem (1998) 41:4196–4198.
- HENRY JR, RUPERT KC, DODD JH et al: Potent inhibitors of the MAP kinase p38. Bioorg. Med. Chem. Lett. (1998) 8:3335–3340.
- WILSON KP, MCMAFFREY PG, HSIAO K et al: The structural basis of the specificity of pyridinylimida-zole inhibitors of p38 map kinase. Chem. Biol. (1997) 4:423–431.
- LIVERTON NJ, BUTCHER JW, CLAIBORNE CF et al: Designand synthesis of potent, selective and orally bioavail-able tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. J. Med. Chem. (1999) 42:2180–2190.
- FERRACCIOLI GF, VX-745 Vertex Pharmaceuticals. Curr.Opin. Anti-in/lam. Immunomod. Invest. Drugs (2000) 2:74–77.
- •Excellent and detailed overview of VX-745.
- Press Release, Vertex Pharmaceuticals (2 November 1999).